Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer

References

• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Doebele RC, Farago AF, et al. Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol. 2019;30:ii48–ii49.
   Web of Science ®Google Scholar
• Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307–1316.
   PubMed Web of Science ®Google Scholar
• Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer. N Engl J Med. 2020;383:813–824.
   PubMed Web of Science ®Google Scholar
• Wolf J, Seto T, Han J-Y, et al. Capmatinib in MET Exon 14–mutated or MET-amplified non–small-cell lung cancer. N Engl J Med. 2020;383:944–957.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371–2381.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
   PubMed Web of Science ®Google Scholar
• Fukuoka M. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237–2246.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.
   PubMed Web of Science ®Google Scholar
• Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018;3(15):e120858.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011;29:2066–2070.
   PubMed Web of Science ®Google Scholar
• Collisson EA, Campbell JD, Brooks AN, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550.
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154–162.
   PubMed Web of Science ®Google Scholar
• Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5.
   PubMed Web of Science ®Google Scholar
• Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12:220–229.
   PubMed Web of Science ®Google Scholar
• Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597:732–737.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5:216ra177.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8:179–184.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13:23–31.
   PubMed Web of Science ®Google Scholar
• Carey KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006;66:8163–8171.
   PubMed Web of Science ®Google Scholar
• Mulloy R, Ferrand A, Kim Y, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 2007;67:2325–2330.
   PubMed Web of Science ®Google Scholar
• Ding PN, Lord SJ, Gebski V, et al. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non–small cell lung cancer. J Thorac Oncol. 2017;12:633–643.
   PubMed Web of Science ®Google Scholar
• Sullivan I, Planchard D. Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line. Front Med. 2017:76.
   Web of Science ®Google Scholar
• Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24:638–646.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Sima CS, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015;121:3212–3220.
   PubMed Web of Science ®Google Scholar
• Beau-Faller M, Prim N, Ruppert A-M-M, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2013;25:126–131.
   PubMed Web of Science ®Google Scholar
• Voon PJ, Tsui DWY, Rosenfeld N, et al. Letter to editor: EGFR Exon 20 insertion A763-Y764insFQEA and response to erlotinib. Mol Cancer Ther. 2013;12:20–25.
   Web of Science ®Google Scholar
• Yang PJC. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX- Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Artic Lancet Oncol. 2015;209:24–26.
   Google Scholar
• V. SL, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:3076–3083.
   PubMed Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125.
   PubMed Web of Science ®Google Scholar
• Hirano T, Yasuda H, Tani T, et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015;6:38789–38803.
   PubMed Web of Science ®Google Scholar
• Floc’h N, Martin MJ, Riess JW, et al. Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions. Mol Cancer Ther. 2018;17:885–896.
   PubMed Web of Science ®Google Scholar
• Fang W, Huang Y, Hong S, et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer. 2019;19:1–9.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Fintelmann FJ, Lv. S, et al. Response to osimertinib in an EGFR Exon 20 insertion-positive lung adenocarcinoma. J Thorac Oncol. 2018;13:e204–e206.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Wang Y, Lv. S, et al. ECOG-ACRIN 5162: a phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. J Clin Oncol. 2020;38:9513.
   Web of Science ®Google Scholar
• Meador CB, Sequist LV, Piotrowsk Z. Targeting EGFR exon 20 insertions in non–small cell lung cancer: recent advances and clinical updates. Cancer Discov. 2021;11:2145–2157.
   PubMed Web of Science ®Google Scholar
• Kim TM, Ock C-Y, Kim M, et al. Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: a multicenter trial of the Korean Cancer Study Group (LU17-19). Ann Oncol. 2019;30:v628.
   Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med. 2002;346:92–98.
   PubMed Web of Science ®Google Scholar
• Noronha V, Choughule A, Patil VM, et al. Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. Onco Targets Ther. 2017;10:2903–2908.
   PubMed Web of Science ®Google Scholar
• Yang G, Li J, Xu H, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186–194.
   PubMed Web of Science ®Google Scholar
• Morita C, Yoshida T, Shirasawa M, et al. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Sci Rep. 2021;11:1–7.
   PubMed Web of Science ®Google Scholar
• Takeda’s EXKIVITYTM (mobocertinib) approved by U.S. FDA as the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC [cited 2021 Oct 4]. Available from: https://www.takeda.com/newsroom/newsreleases/2021/takeda-exkivity-mobocertinib-approved-by-us-fda/
   Google Scholar
• FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer [cited 2021 Oct 12]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer
   Google Scholar
• Goldberg SB, Redman MW, Lilenbaum R, et al. Randomized trial of Afatinib plus cetuximab versus Afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer: final results from SWOG S1403. J Clin Oncol. 2020;38:4076–4085.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376:629–640.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of JMT101 combined with afatinib (or osimertinib) in patients with non-small cell lung cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT04448379
   Google Scholar
• Kim E, Kim H, Suh K, et al. Metabolite identification of a new tyrosine kinase inhibitor, HM781-36B, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2013;27:1183–1195.
   PubMed Web of Science ®Google Scholar
• Cha MY, Lee KO, Kim M, et al. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012;130:2445–2454.
   PubMed Web of Science ®Google Scholar
• Heymach J, Negrao M, Robichaux J, et al. OA02.06 A Phase II trial of poziotinib in EGFR and HER2 exon 20 mutant Non-Small Cell Lung Cancer (NSCLC). AACR. 2020;2020:S323–S324.
   Google Scholar
• Le X, Goldman JW, Clarke JM, et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. J Clin Oncol. 2020;38:9514.
   Web of Science ®Google Scholar
• Sacher A, Le X, Cornelissen R, et al. 36MO - Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer. Ann Oncol. 2021;32:S14–S19.
   Web of Science ®Google Scholar
• Gonzalvez F, Zhu X, Huang W-S, et al. Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models. Cancer Res. 2016;76:2644.
   Google Scholar
• Ramalingam SS, Zhou C, Kim TM, et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. J Clin Oncol. 2021;39:9014.
   Web of Science ®Google Scholar
• Riely GJ, Neal JW, Camidge DR, et al. Activity and safety of mobocertinib (Tak-788) in previously treated non–small cell lung cancer with egfr exon 20 insertion mutations from a phase i/ii trial. Cancer Discov. 2021;11:1688–1699.
   PubMed Web of Science ®Google Scholar
• TAK-788 as first-line treatment versus platinum-based chemotherapy for Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 insertion mutations.
   Google Scholar
• Hasako S, Terasaka M, Abe N, et al. TAS6417, A novel EGFR inhibitor targeting Exon 20 insertion mutations. Mol Cancer Ther. 2018;17:1648–1658.
   PubMed Web of Science ®Google Scholar
• Udagawa H, Hasako S, Ohashi A, et al. TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations. Mol Cancer Res. 2019;17:2233–2243.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Yu HA, Yang JC-H, et al. Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). J Clin Oncol. 2021;39:9077.
   Web of Science ®Google Scholar
• Schram AM, Rodon Ahnert J, Patel MR, et al. Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: a First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allos. J Clin Oncol. 2021;39:3086.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Wang M, Mitchell P, et al. Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. J Clin Oncol. 2021;39:9008.
   Web of Science ®Google Scholar
• Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS Phase I study. J Clin Oncol. 2021;39(30):3391–3402.
   PubMed Web of Science ®Google Scholar
• Tsigelny IF, Wheler JJ, Greenberg JP, et al. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 2015;6:6029–6039.
   PubMedGoogle Scholar
• Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011;11:777–792.
   PubMed Web of Science ®Google Scholar
• Wheler JJ, Tsimberidou AM, Falchook GS, et al. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther. 2013;12:2167–2175.
   PubMed Web of Science ®Google Scholar
• van Veggel B, van der Wekken AJ, Paats M, et al. Interim results of a phase II single arm trial combining Afatinib with cetuximab in patients with EGFRex20ins positive NSCLC. J Clin Oncol. 2021;39:9112.
   Web of Science ®Google Scholar
• Riess JW, Groshen SG, Reckamp KL, et al. Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: an ETCTN California cancer consortium phase I study. J Clin Oncol. 2019;37:9057.
   Web of Science ®Google Scholar
• Neijssen J, Cardoso RMF, Chevalier KM, et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021;296:100641.
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500.
   PubMed Web of Science ®Google Scholar
• Liu X, Yao W, Newton RC, et al. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs. 2008;17:997–1011.
   PubMed Web of Science ®Google Scholar
• Dulak AM, Gubish CT, Stabile LP, et al. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011 3033. 2011;30:3625–3635.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043.
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih J-Y, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci. 2007;104:20932–20937.
   PubMed Web of Science ®Google Scholar
• Husain B, Ellerman D. Expanding the boundaries of biotherapeutics with bispecific antibodies. BioDrugs 325. 2018. 2018;32:441–464.
   PubMed Web of Science ®Google Scholar
• M K-B, S J, W D. The sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004;6:75–84.
   PubMed Web of Science ®Google Scholar
• Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor–resistant lung tumors. Cancer Res. 2016;76:3942–3953.
   PubMed Web of Science ®Google Scholar
• Yun J, Lee S-H, Kim S-Y, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR–MET bispecific antibody, in diverse models of EGFR Exon 20 insertion–driven NSCLC. Cancer Discov. 2020;10:1194–1209.
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther. 2020;19:2044–2056. **This article describes the mechanisms of action of amivantamab including receptor downmodulation and monocyte/macrophage trogocytosis.
   PubMed Web of Science ®Google Scholar
• van Veggel B, de Langen AJ, Hashemi SMS, et al. Afatinib and cetuximab in four patients with EGFR Exon 20 insertion–positive advanced NSCLC. J Thorac Oncol. 2018;13:1222–1226.
   PubMed Web of Science ®Google Scholar
• Li J, Shen L, Gong J, et al. A multicenter, open-label, phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of JMT-101 in patients (pts) with advanced colorectal cancer (ACC). J Clin Oncol. 2020;38:e16025–e16025.
   Web of Science ®Google Scholar
• A study of amivantamab and lazertinib in people with Non-Small Cell Lung Cancer (NSCLC) [cited 2021 Oct 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT04965090
   Google Scholar
• Cavaco M, Gaspar D, Castanho MA, et al. Antibodies for the treatment of brain metastases, a dream or a reality? Pharmaceutics. 2020;12:62.
   Web of Science ®Google Scholar
• Dhillon S. Lazertinib: first Approval. Drugs. 2021;81:1107–1113.
   PubMedGoogle Scholar
• Yun J, Hong MH, Kim SY, et al. YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer. Clin Cancer Res. 2019;25:2575–2587.
   PubMed Web of Science ®Google Scholar
• Kim S-W, Ahn M-J, Han J-Y, et al. Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: data from a phase I/II study. J Clin Oncol. 2020;38:9571.
   Web of Science ®Google Scholar
• Shu CA, Goto K, Cho BC, et al. CHRYSALIS-2: a phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC. J Clin Oncol. 2021;39: TPS9132–TPS9132.
   Web of Science ®Google Scholar
• Krebs M, Johnson ML, Cho BC, et al. Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study. J Clin Oncol. 2021;39: TPS3150–TPS3150.
   Web of Science ®Google Scholar
• A study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in participants with advanced or metastatic non-small cell lung cancer characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 insertions [cited 2021 Oct 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT04538664
   Google Scholar
• Shreeve SM, Martinez M, Verheijen RB, et al. P76.73 MARIPOSA: randomized Phase 3 study of first-line Amivantamab + Lazertinib vs osimertinib vs lazertinib in EGFR-mutant NSCLC. J Thorac Oncol. 2021;16:S620–S621.
   Web of Science ®Google Scholar
• A study of amivantamab and lazertinib in combination with platinum-based chemotherapy compared with platinum-based chemotherapy in patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2) [cited 2021 Oct 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT04988295
   Google Scholar
• Syed YY. Amivantamab: first approval. Drugs. 2021;81:1349–1353.
   PubMed Web of Science ®Google Scholar
• Bauml J, Cho BC, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J Clin Oncol. 2021;39:9006.
   Web of Science ®Google Scholar
• Bray SM, Lee J, Kim ST, et al. Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Sci Rep 91. 2019. 2019;9:1–13.
   PubMed Web of Science ®Google Scholar
• Hendriks LEL, Smit EF, Vosse BAH, et al. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? Lung Cancer. 2014;84:86–91.
   PubMed Web of Science ®Google Scholar